Emily Etheridge
Family · Baileyton, ALNPI 1770258287
Payments from drug & device makers
Across 43 payments — averaging $29.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galt Pharmaceuticals, LLC$457
- AbbVie$309
- Novo Nordisk$80
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$71
- Atland Pharmaceuticals, LLC$62
- Antares Pharma, Inc.$62
- plus $247 from 9 others
What the payments were for
- Food & beverage$1,289100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galt Pharmaceuticals, LLC | 1 | $457 |
| AbbVie | 16 | $309 |
| Novo Nordisk | 4 | $80 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $71 |
| Atland Pharmaceuticals, LLC | 2 | $62 |
| Antares Pharma, Inc. | 3 | $62 |
| Harmony Biosciences LLC | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Pfizer | 2 | $39 |
| Tolmar, Inc. | 1 | $30 |
| Ironshore Pharmaceuticals Inc. | 1 | $24 |
| GSK | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
| AstraZeneca | 1 | $13 |
| Halozyme Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orphengesic Forte$457
- Oravig$457
How this compares
$1,289 in reported general payments places this provider in the 70th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 45 | $45,890 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $36,620 |
| EliquisApixaban | 44 | $31,767 |
| MounjaroTirzepatide | 19 | $19,932 |
| RexultiBrexpiprazole | 13 | $18,948 |
| JardianceEmpagliflozin | 17 | $14,663 |
| MyrbetriqMirabegron | 20 | $11,204 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $10,156 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $8,522 |
| LinzessLinaclotide | 16 | $8,201 |
| PremarinEstrogens, Conjugated | 11 | $3,908 |
| Metaxalone | 15 | $3,560 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 153 | $3,077 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,874 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $1,695 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $80 | $45,89045 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $17 | $45,14271 claims |
| PfizerEliquis, Premarin | $39 | $35,67555 claims |
| Lilly USA, LLCMounjaro | $14 | $19,93219 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $41 | $18,94813 claims |
| AbbVieLinzess | $309 | $8,20116 claims |
| AstraZenecaSymbicort | $13 | $2,87412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,415 family providers in Alabama.
Other family in Baileyton
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.